NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Shanghai Yingli Pharmaceutical Co., Ltd.

Shanghai Yingli Pharmaceutical Co., Ltd.

Private
ShanghaiHealthcare & Life Scienceshttp://www.yl-pharma.com/cn/index.html

Last Round

Series A++

Mar 21, 2024

Total Funding Raised

$50M

Company Overview

Shanghai Yingli Pharmaceutical Co., Ltd. is a clinical-stage biotechnology company that researches and develops innovative oral small-molecule drugs for the treatment of oncology and metabolic diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologysmall-molecule drugsoncologyPI3Kδ inhibitordrug discoveryclinical-stage biotechbiopharmahematological malignanciessolid tumorsclinical trialsprecision medicinedrug pipelinemetabolic diseaselicensing agreementtherapeutic development

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Shanghai Yingli Pharmaceutical Co., Ltd. Comps

Public and private peers based on sector, stage, and business model.

Shanghai Yingli Pharmaceutical Co., Ltd. comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Shanghai Yingli Pharmaceutical Co., Ltd. Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A++Mar 21, 2024
Series A ExtensionNov 8, 2023
StrategicFeb 8, 2021
Series AFeb 2, 2021

Shanghai Yingli Pharmaceutical Co., Ltd. Investors

Notable investors and investment history

Shanghai Yingli Pharmaceutical Co., Ltd. investors
InvestorRounds
DYEE CapitalSeries A Extension
中南创投基金Series A
CICC CapitalSeries A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Nov 8, 2023

    Raised Series A Extension round with CICC Capital and DYEE Capital.

Shanghai Yingli Pharmaceutical Co., Ltd. Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Shanghai Yingli Pharmaceutical Co., Ltd. Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Shanghai Yingli Pharmaceutical Co., Ltd.'s valuation, stock price, and market status.

Firmographic Details

HeadquartersShanghai
Year Founded2011
Last FundingMar 21, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.